Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Epithalon vs Livagen — Peptide Comparison

At a Glance Quickcomparison Dose Range Epithalon 5–10 mg Livagen 2–10 mg Frequency Once daily Administration Subcutaneous injection Intramuscular injection Cycle Length 4-6 weeks 8-12 weeks Onset Speed Gradual (3-4 weeks) Evidence Level Limited human trials Ef

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Epithalon

5–10 mg

Livagen

2–10 mg

Frequency

Once daily

Administration

Subcutaneous injection

Intramuscular injection

Cycle Length

4-6 weeks

8-12 weeks

Onset Speed

Gradual (3-4 weeks)

Evidence Level

Limited human trials

Efficacy

Benefitratings

Telomere Protection

Sleep Quality

Cellular Longevity

Cell Renewal

Liver Support

DNA Protection

Technical Data

Compoundspecifications

Molecular Formula

C14H22N4O9

Molecular Weight

390.35 g/mol

Half-Life

2-4 hours (estimated)

Bioavailability

High when injected subcutaneously

CAS Number

307297-39-8

C18H31N5O9

461.5 g/mol

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)

Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli

Not assigned (research compound)

Protocols

Dosingtiers

standard

5-10 mg

10-20 day course, repeated 1-3 times per year

Subcutaneous injection is the most common route used in practice, mirroring the dose used in the Russian intramuscular clinical literature [6]. Typically run as a short 10-20 day course a few times per year [3].

Intramuscular dosing of 5-10 mg/day for 10-20 days is the form used in Khavinson's original Russian clinical work in older adults [6].

10-day course (50-100 mg total)

Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical [6].

Applications

Bestsuited for

Longevity Enthusiasts

If you're serious about healthy aging and want to support your cells at the deepest level, Epithalon targets one of the fundamental mechanisms of cellular aging—telomere shortening. It's like giving your cells' protective caps a little extra reinforcement.

Sleep Quality Seekers

Epithalon helps regulate melatonin production by supporting your pineal gland. Many users report better sleep quality and more consistent sleep-wake cycles, especially those who've noticed their sleep getting worse with age.

Those Concerned About Oxidative Stress

Beyond its telomere effects, Epithalon acts as an antioxidant. If you're exposed to environmental stressors, have a demanding lifestyle, or simply want extra cellular protection, this peptide offers multiple mechanisms of support.

Immune System Support (Age-Related)

As we age, our immune system naturally weakens—a process called immunosenescence. Research suggests Epithalon may help maintain immune function by supporting the thymus and immune cell health, potentially keeping your defenses stronger as you age.

Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells

Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting liver function and hepatoprotection in the context of aging

Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Restoring protein synthesis and ribosomal function in elderly individuals

Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Khavinson bioregulator protocols for anti-aging and longevity

Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Injection site redness

Mild headache

Temporary fatigue

Uncommon

Vivid dreams

Sleep pattern changes

Serious

Allergic reaction

Injection site reaction

Mild fatigue

Digestive enzyme changes

Transient flu-like symptoms

No documented serious adverse effects

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Epithalon has shown a favorable safety profile across decades of research, primarily conducted in Russia. Studies spanning up to 15 years of follow-up have reported no severe adverse events in older adults using Epithalon or its natural precursor Epithalamin. The peptide appears well-tolerated with minimal side effects, mostly limited to mild injection site reactions. However, large-scale clinical trials outside of Russia are still needed.

Contraindications

xPregnancy or planning to become pregnant

xCurrently breastfeeding

xActive cancer or history of cancer

xKnown allergy to peptide components

xChildren and adolescents

Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)

xPregnancy and breastfeeding — insufficient reproductive safety data

xActive autoimmune conditions in flare without physician supervision

xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism

Decision Guide

Which isright for you?

Choose Epithalon if...

Longevity and healthy aging

Cellular rejuvenation

Sleep quality improvement

Antioxidant support

Choose Livagen if...

Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells

Supporting liver function and hepatoprotection in the context of aging

Restoring protein synthesis and ribosomal function in elderly individuals

Khavinson bioregulator protocols for anti-aging and longevity

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status FDA approved for this use Safety Overview Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible. Contraindications xKnown allergy to cetrorelix or any ingredient xPregnancy (it may harm the developing baby) xUndiagnosed vaginal bleeding xSevere liver or kidney disease xLatex allergy (some syringes contain latex) Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted. xPregnancy or suspected pregnancy xBreastfeeding xKnown allergies to any medication component xOvarian cysts larger than 3cm Decision Guide

Source: peptideinitiative.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

Benefitratings

Fighting Drug-Resistant Infections Bloodstream Infections Skin Infection Treatment Fighting Resistant Infections Stopping Bacterial Toxins Wound Protection Technical Data

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →